-
1
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008; 26:1626–1634.
-
(2008)
Journal of Clinical Oncology
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
Van Cutsem, E.4
Siena, S.5
Freeman, D.J.6
Juan, T.7
Sikorski, R.8
Suggs, S.9
Radinsky, R.10
Patterson, S.D.11
Chang, D.D.12
-
2
-
-
73149115341
-
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
-
Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of Clinical Oncology 2009; 27(33):5538–5546.
-
(2009)
Journal of Clinical Oncology
, vol.27
, Issue.33
, pp. 5538-5546
-
-
Johnston, S.1
Pippen, J.2
Pivot, X.3
Lichinitser, M.4
Sadeghi, S.5
Dieras, V.6
Gomez, H.L.7
Romieu, G.8
Manikhas, A.9
Kennedy, M.J.10
Press, M.F.11
Maltzman, J.12
Florance, A.13
O'Rourke, L.14
Oliva, C.15
Stein, S.16
Pegram, M.17
-
3
-
-
26844457534
-
The distinctive nature of HER2-positive breast cancers
-
Burstein HJ. The distinctive nature of HER2-positive breast cancers. New England Journal of Medicine 2005; 353:1652–1654.
-
(2005)
New England Journal of Medicine
, vol.353
, pp. 1652-1654
-
-
Burstein, H.J.1
-
4
-
-
0034466679
-
Debate: Subgroup analyses in clinical trials: fun to look at – but don't believe them!
-
Sleight P. Debate: Subgroup analyses in clinical trials: fun to look at – but don't believe them! Current Controlled Trials in Cardiovascular Medicine 2000; 1:25–27.
-
(2000)
Current Controlled Trials in Cardiovascular Medicine
, vol.1
, pp. 25-27
-
-
Sleight, P.1
-
5
-
-
33645895554
-
The challenge of subgroup analyses – reporting without distorting
-
Lagakos SW. The challenge of subgroup analyses – reporting without distorting. New England Journal of Medicine 2006; 354:1667–1669.
-
(2006)
New England Journal of Medicine
, vol.354
, pp. 1667-1669
-
-
Lagakos, S.W.1
-
7
-
-
85014372950
-
-
(accessed 20 February 2015)
-
Alimta (pemetrexed for injection) label, 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021462s045lbl.pdf (accessed 20 February 2015)
-
(2013)
Alimta (pemetrexed for injection) label
-
-
-
8
-
-
85014352060
-
-
(accessed 20 February 2015)
-
Valcyte (valganciclovir hydrochloride) label, 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021304s010,022257s004lbl.pdf (accessed 20 February 2015)
-
(2013)
Valcyte (valganciclovir hydrochloride) label
-
-
-
9
-
-
33846447795
-
The probability of observing negative subgroup results when the treatment effect is positive and homogenous across all subgroups
-
Li Z, Chuang-Stein C, Hoseyni C. The probability of observing negative subgroup results when the treatment effect is positive and homogenous across all subgroups. Drug Information Journal 2007; 41:47–56.
-
(2007)
Drug Information Journal
, vol.41
, pp. 47-56
-
-
Li, Z.1
Chuang-Stein, C.2
Hoseyni, C.3
-
10
-
-
77953682084
-
Regional differences in multinational clinical trials: anticipating chance variation
-
Marschner I. Regional differences in multinational clinical trials: anticipating chance variation. Clinical Trials 2010; 7:147–156.
-
(2010)
Clinical Trials
, vol.7
, pp. 147-156
-
-
Marschner, I.1
-
11
-
-
85014390816
-
-
Code of Federal Regulation, 21CFR314.126,, (accessed 20 February 2015)
-
Food and Drug Administration. Health Human Services, Code of Federal Regulation, 21CFR314.126, 2013. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.126 (accessed 20 February 2015)
-
(2013)
Health Human Services
-
-
-
12
-
-
84865693205
-
-
(accessed 28 January 2015)
-
Food and Drug Administration Safety and Innovation Act (FDASIA), 2012. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/ucm20027187.htm (accessed 28 January 2015).
-
(2012)
Food and Drug Administration Safety and Innovation Act (FDASIA)
-
-
-
13
-
-
85014357948
-
-
E9 Statistical Principles for Clinical Trials (ICH E9 guidance),, (accessed 28 January 2015)
-
International Conference on Harmonization International Conference on Harmonization (ICH) Guidance, E9 Statistical Principles for Clinical Trials (ICH E9 guidance), 1998. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf (accessed 28 January 2015).
-
(1998)
International Conference on Harmonization International Conference on Harmonization (ICH) Guidance
-
-
-
16
-
-
84950314815
-
Statistical considerations on subgroup analysis in clinical trials
-
Alosh M, Fritsch F, Huque M, Mahjoob K, Pennello G, Rothmann R, Russek-Cohen E, Smith F, Wilson S, Yue L. Statistical considerations on subgroup analysis in clinical trials. Statistics in Biopharmaceutical Research 2015; 7:286–303.
-
(2015)
Statistics in Biopharmaceutical Research
, vol.7
, pp. 286-303
-
-
Alosh, M.1
Fritsch, F.2
Huque, M.3
Mahjoob, K.4
Pennello, G.5
Rothmann, R.6
Russek-Cohen, E.7
Smith, F.8
Wilson, S.9
Yue, L.10
-
17
-
-
84955256935
-
Methods for identification and confirmation of targeted subgroups in clinical trials: a systematic review
-
Ondra T, Dmitrienko A, Friede T, Graf A, Miller F, Stallard N, Posch M. Methods for identification and confirmation of targeted subgroups in clinical trials: a systematic review. Journal of Biopharmaceutical Statistics 2016; 26:99–119.
-
(2016)
Journal of Biopharmaceutical Statistics
, vol.26
, pp. 99-119
-
-
Ondra, T.1
Dmitrienko, A.2
Friede, T.3
Graf, A.4
Miller, F.5
Stallard, N.6
Posch, M.7
-
18
-
-
84911962987
-
Multiplicity and replicability: two sides of the same coin
-
Bretz F, Westfall PH. Multiplicity and replicability: two sides of the same coin. Pharmaceutical Statistics 2014; 13:343–344.
-
(2014)
Pharmaceutical Statistics
, vol.13
, pp. 343-344
-
-
Bretz, F.1
Westfall, P.H.2
-
19
-
-
79959271989
-
Bayesian models for subgroup analysis in clinical trials
-
Jones HE, Ohlssen DI, Neuenschwander B, Racine A, Branson M. Bayesian models for subgroup analysis in clinical trials. Clinical Trials 2011; 8:129–143.
-
(2011)
Clinical Trials
, vol.8
, pp. 129-143
-
-
Jones, H.E.1
Ohlssen, D.I.2
Neuenschwander, B.3
Racine, A.4
Branson, M.5
-
20
-
-
84891752239
-
Reliably basing conclusions on subgroups of randomized clinical trials
-
Koch A, Framke T. Reliably basing conclusions on subgroups of randomized clinical trials. Journal of Biopharmaceutical Statistics 2014; 24:42–57.
-
(2014)
Journal of Biopharmaceutical Statistics
, vol.24
, pp. 42-57
-
-
Koch, A.1
Framke, T.2
-
21
-
-
0035826096
-
Recombinant human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: efficacy and safety of recombinant human activated protein C for severe sepsis
-
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbr JD, Ely EW, Fisher CJ Jr. Recombinant human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine 2001; 344:699–709.
-
(2001)
New England Journal of Medicine
, vol.344
, pp. 699-709
-
-
Bernard, G.R.1
Vincent, J.L.2
Laterre, P.F.3
LaRosa, S.P.4
Dhainaut, J.F.5
Lopez-Rodriguez, A.6
Steingrub, J.S.7
Garber, G.E.8
Helterbr, J.D.9
Ely, E.W.10
Fisher, C.J.11
-
22
-
-
0037251585
-
PROWESS Investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis
-
Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR. PROWESS Investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Critical Care Medicine 2003; 31:12–19.
-
(2003)
Critical Care Medicine
, vol.31
, pp. 12-19
-
-
Ely, E.W.1
Laterre, P.F.2
Angus, D.C.3
Helterbrand, J.D.4
Levy, H.5
Dhainaut, J.F.6
Vincent, J.L.7
Macias, W.L.8
Bernard, G.R.9
-
23
-
-
0030590746
-
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee
-
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348(9038):1329–1339.
-
(1996)
Lancet
, vol.348
, Issue.9038
, pp. 1329-1339
-
-
-
24
-
-
78049293287
-
No inconsistent trial assessments by NICE and IQWiG: different assessment goals may lead to different assessment results regarding subgroup analyses
-
Bender R, Koch A, Skipka G, Kaiser T, Lange S. No inconsistent trial assessments by NICE and IQWiG: different assessment goals may lead to different assessment results regarding subgroup analyses. Journal of Clinical Epidemiology 2010; 63:1305–1307.
-
(2010)
Journal of Clinical Epidemiology
, vol.63
, pp. 1305-1307
-
-
Bender, R.1
Koch, A.2
Skipka, G.3
Kaiser, T.4
Lange, S.5
-
25
-
-
78049249374
-
Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed
-
Hasford J, Bramlag P, Koch GG, Lehmacher W, Einhäupl K, Rothwell PM. Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed. Journal of Clinical Epidemiology 2010; 63:1298–1304.
-
(2010)
Journal of Clinical Epidemiology
, vol.63
, pp. 1298-1304
-
-
Hasford, J.1
Bramlag, P.2
Koch, G.G.3
Lehmacher, W.4
Einhäupl, K.5
Rothwell, P.M.6
-
26
-
-
4644225190
-
Doxil study 30–49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
-
Gordon AN, Tonda M, Sun S, Rackoff W. Doxil study 30–49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecologic Oncology 2004; 95(1):1–8.
-
(2004)
Gynecologic Oncology
, vol.95
, Issue.1
, pp. 1-8
-
-
Gordon, A.N.1
Tonda, M.2
Sun, S.3
Rackoff, W.4
-
27
-
-
84891765135
-
Standardization for subgroup analysis in randomized controlled trials
-
Varadhan R, Wang SJ. Standardization for subgroup analysis in randomized controlled trials. Journal of Biopharmaceutical Statistics 2014; 24(1):154–167.
-
(2014)
Journal of Biopharmaceutical Statistics
, vol.24
, Issue.1
, pp. 154-167
-
-
Varadhan, R.1
Wang, S.J.2
-
29
-
-
0022072706
-
Testing for qualitative interaction between treatment effects and patient subsets
-
Gail M, Simon R. Testing for qualitative interaction between treatment effects and patient subsets. Biometrics 1985; 41:361–372.
-
(1985)
Biometrics
, vol.41
, pp. 361-372
-
-
Gail, M.1
Simon, R.2
-
30
-
-
0002255973
-
Statistical aspects of cancer trials
-
In, Halnan KE, (ed)., Chapman and Hall, London, UK
-
Peto R. Statistical aspects of cancer trials. In Treatment of Cancer, Halnan KE (ed). Chapman and Hall: London, UK, 1982; 867–871.
-
(1982)
Treatment of Cancer
, pp. 867-871
-
-
Peto, R.1
-
31
-
-
1842453957
-
Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test
-
Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology 2004; 57:229–236.
-
(2004)
Journal of Clinical Epidemiology
, vol.57
, pp. 229-236
-
-
Brookes, S.T.1
Whitely, E.2
Egger, M.3
Smith, G.D.4
Mulheran, P.A.5
Peters, T.J.6
-
32
-
-
84944151465
-
Statistical perspectives on subgroup analysis: testing for heterogeneity and evaluating error rate for the complementary subgroup
-
Alosh M, Huque MF, Koch GG. Statistical perspectives on subgroup analysis: testing for heterogeneity and evaluating error rate for the complementary subgroup. Journal of Biopharmaceutical Statistics 2015; 25:1161–1178.
-
(2015)
Journal of Biopharmaceutical Statistics
, vol.25
, pp. 1161-1178
-
-
Alosh, M.1
Huque, M.F.2
Koch, G.G.3
-
33
-
-
84889820624
-
For the society for clinical trials (SCT) multi-regional clinical trial consistency working group. Graphical assessment of consistency in treatment effect among countries in multi-regional clinical trials
-
Chen J, Zheng H, Quan H, Li G, Gallo P, Ouyang SP, Binkowitz B, Ting N, Tanaka YX, Luo Ibia E. For the society for clinical trials (SCT) multi-regional clinical trial consistency working group. Graphical assessment of consistency in treatment effect among countries in multi-regional clinical trials. Clinical Trials 2013; 10:842–851.
-
(2013)
Clinical Trials
, vol.10
, pp. 842-851
-
-
Chen, J.1
Zheng, H.2
Quan, H.3
Li, G.4
Gallo, P.5
Ouyang, S.P.6
Binkowitz, B.7
Ting, N.8
Tanaka, Y.X.9
Luo Ibia, E.10
-
34
-
-
84921626814
-
Methods for exploring treatment effect heterogeneity in subgroup analysis: an application to global clinical trials
-
Schou IM, Marschner IC. Methods for exploring treatment effect heterogeneity in subgroup analysis: an application to global clinical trials. Pharmaceutical Statistics 2015; 14:44–55.
-
(2015)
Pharmaceutical Statistics
, vol.14
, pp. 44-55
-
-
Schou, I.M.1
Marschner, I.C.2
-
35
-
-
79957529687
-
Chain procedure: a class of flexible closed testing procedures with clinical trial application
-
Millen B, Dmitrienko A. Chain procedure: a class of flexible closed testing procedures with clinical trial application. Statistics in Biopharmaceutical Research 2011; 3:14–30.
-
(2011)
Statistics in Biopharmaceutical Research
, vol.3
, pp. 14-30
-
-
Millen, B.1
Dmitrienko, A.2
-
36
-
-
84876969027
-
Multiplicity considerations for subgroup analysis subject to consistency constraints
-
Alosh M, Huque MF. Multiplicity considerations for subgroup analysis subject to consistency constraints. Biometrical Journal 2013; 55:444–462.
-
(2013)
Biometrical Journal
, vol.55
, pp. 444-462
-
-
Alosh, M.1
Huque, M.F.2
-
37
-
-
84888130933
-
A regulatory perspective on essential considerations in design and analysis of subgroups when correctly classified
-
Wang SJ, Hung J. A regulatory perspective on essential considerations in design and analysis of subgroups when correctly classified. Journal of Biopharmaceutical Statistics 2014; 24:19–41.
-
(2014)
Journal of Biopharmaceutical Statistics
, vol.24
, pp. 19-41
-
-
Wang, S.J.1
Hung, J.2
-
38
-
-
84891810976
-
An overview of statistical planning to address subgroups in confirmatory clinical trials
-
Koch GG, Schwartz T. An overview of statistical planning to address subgroups in confirmatory clinical trials. Journal of Biopharmaceutical Statistics 2014; 24:72–93.
-
(2014)
Journal of Biopharmaceutical Statistics
, vol.24
, pp. 72-93
-
-
Koch, G.G.1
Schwartz, T.2
-
39
-
-
85014380575
-
-
(accessed 28 January 2015)
-
Xigris label, 2007. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125029s080LBL.pdf (accessed 28 January 2015).
-
(2007)
Xigris label
-
-
-
40
-
-
25444492831
-
For the administration of drotrecogin alfa (activated) in early stage severe sepsis (ADDRESS) study group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
-
Abraham E, Laterre P-F, Garg R, Levy H, Talwar D, Trzaskoma B, François B, Guy J, Brückmann M, Rea-Neto Á, Rossaint R, Perrotin D, Armin Sablotzki A, Arkins N, Utterback B, Macias W. For the administration of drotrecogin alfa (activated) in early stage severe sepsis (ADDRESS) study group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New England Journal of Medicine 2005; 353:1332–1341.
-
(2005)
New England Journal of Medicine
, vol.353
, pp. 1332-1341
-
-
Abraham, E.1
Laterre, P.-F.2
Garg, R.3
Levy, H.4
Talwar, D.5
Trzaskoma, B.6
François, B.7
Guy, J.8
Brückmann, M.9
Rea-Neto, Á.10
Rossaint, R.11
Perrotin, D.12
Armin Sablotzki, A.13
Arkins, N.14
Utterback, B.15
Macias, W.16
-
41
-
-
0141883593
-
Discussion for “p-value adjustments for subgroup analyses
-
Koch GG. Discussion for “p-value adjustments for subgroup analyses.”. Journal of Biopharmaceutical Statistics 1997; 7(2):323–331.
-
(1997)
Journal of Biopharmaceutical Statistics
, vol.7
, Issue.2
, pp. 323-331
-
-
Koch, G.G.1
-
42
-
-
61749083299
-
A flexible strategy for testing subgroups and overall population
-
Alosh M, Huque MF. A flexible strategy for testing subgroups and overall population. Statistics in Medicine 2009; 28:3–23.
-
(2009)
Statistics in Medicine
, vol.28
, pp. 3-23
-
-
Alosh, M.1
Huque, M.F.2
-
44
-
-
78449283356
-
Enrichment of clinical study populations. State of the art
-
Temple R. Enrichment of clinical study populations. State of the art. Nature Publishing Group 2010; 88(6):774–778.
-
(2010)
Nature Publishing Group
, vol.88
, Issue.6
, pp. 774-778
-
-
Temple, R.1
-
45
-
-
27744537954
-
Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
-
Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 2005; 11:7872–7878.
-
(2005)
Clinical Cancer Research
, vol.11
, pp. 7872-7878
-
-
Freidlin, B.1
Simon, R.2
-
46
-
-
66349125688
-
Adaptive patient enrichment designs in therapeutic trials
-
Wang SJ, Hung HM, O'Neill RT. Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 2009; 51:358–374.
-
(2009)
Biometrical Journal
, vol.51
, pp. 358-374
-
-
Wang, S.J.1
Hung, H.M.2
O'Neill, R.T.3
-
47
-
-
34648840242
-
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
-
Wang SJ, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 2007; 6:227–244.
-
(2007)
Pharmaceutical Statistics
, vol.6
, pp. 227-244
-
-
Wang, S.J.1
O'Neill, R.T.2
Hung, H.M.3
-
48
-
-
61349150491
-
Optimizing trial design: sequential, adaptive, and enrichment strategies
-
Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation 2009; 119:597–605.
-
(2009)
Circulation
, vol.119
, pp. 597-605
-
-
Mehta, C.1
Gao, P.2
Bhatt, D.L.3
Harrington, R.A.4
Skerjanec, S.5
Ware, J.H.6
-
50
-
-
34547529442
-
A method for testing a prespecified subgroup in clinical trials
-
Song Y, Chi GY. A method for testing a prespecified subgroup in clinical trials. Statistics in Medicine 2007; 26:3535–3549.
-
(2007)
Statistics in Medicine
, vol.26
, pp. 3535-3549
-
-
Song, Y.1
Chi, G.Y.2
-
51
-
-
84876440727
-
Testing each hypothesis marginally at alpha while still controlling FWER: how and when
-
Li J. Testing each hypothesis marginally at alpha while still controlling FWER: how and when. Statistics in Medicine 2013; 32:1730–1738.
-
(2013)
Statistics in Medicine
, vol.32
, pp. 1730-1738
-
-
Li, J.1
-
52
-
-
15944368765
-
A fixed-sequence Bonferroni procedure for testing multiple endpoints
-
Wiens B. A fixed-sequence Bonferroni procedure for testing multiple endpoints. Pharmaceutical Statistics 2003; 2:211–215.
-
(2003)
Pharmaceutical Statistics
, vol.2
, pp. 211-215
-
-
Wiens, B.1
-
53
-
-
60749089513
-
A graphical approach to sequentially rejective multiple testing procedures
-
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple testing procedures. Statistics in Medicine 2009; 28:586–604.
-
(2009)
Statistics in Medicine
, vol.28
, pp. 586-604
-
-
Bretz, F.1
Maurer, W.2
Brannath, W.3
Posch, M.4
-
54
-
-
64549084568
-
A recycling framework for the construction of Bonferroni-based multiple tests
-
Burman CF, Sonesson C, Guilbaud O. A recycling framework for the construction of Bonferroni-based multiple tests. Statistics in Medicine 2009; 28:739–761.
-
(2009)
Statistics in Medicine
, vol.28
, pp. 739-761
-
-
Burman, C.F.1
Sonesson, C.2
Guilbaud, O.3
-
55
-
-
84873817347
-
A statistical framework for decision making in confirmatory multi population tailoring clinical trials
-
Millen B, Dmitrienko A, Ruberg S, Shen L. A statistical framework for decision making in confirmatory multi population tailoring clinical trials. Drug Information Journal 2012; 46:647–656.
-
(2012)
Drug Information Journal
, vol.46
, pp. 647-656
-
-
Millen, B.1
Dmitrienko, A.2
Ruberg, S.3
Shen, L.4
-
56
-
-
35348821173
-
A flexible fixed-sequence testing method for hierarchically ordered correlated endpoints in clinical trials
-
Huque MF, Alosh M. A flexible fixed-sequence testing method for hierarchically ordered correlated endpoints in clinical trials. Journal of Statistical Planning and Inference 2008; 138:321–335.
-
(2008)
Journal of Statistical Planning and Inference
, vol.138
, pp. 321-335
-
-
Huque, M.F.1
Alosh, M.2
|